The development of innovative microinvasive glaucoma surgery (MIGS) procedures has given us an opportunity to fill a long-existing niche in the glaucoma management. Traditionally, the treatment for mild to moderate 
Trabectome
Ab interno trabeculotomy by the Trabectome ® device (NeoMedix, Tustin, USA) uses a high frequency electrocautery to remove a strip of trabecular meshwork and the inner wall of Schlemm's canal (SC). 2 The rationale for this angle surgery is the removal of the area of greatest resistance to aqueous outflow while achieving some retraction of the incision edges by heat effect and consequently reducing potential scarring. 
31
of two iStents, and 41% at 6 months after implantation of three iStents.
The authors found a notable lack of published research on rates of early and late post-operative complications. The most common complications were related to iStent malposition or obstruction.
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The XEN ® Gel Stent (AqueSys Implant) was created by AqueSys Inc (Aliso Viejo, CA, USA). It is made out of a soft collagen-derived gelatin that is known to be non-inflammatory. The goal of the implantation is to create an aqueous humor outflow pathway from the anterior chamber to the subconjunctival space. The implant is 6 mm long and about the width of a human hair, preloaded in a needle tip injector. Similar to the other implants, it can be performed in conjunction with cataract surgery. It is an investigational device currently undergoing clinical trials.
MIGS technology opens an exciting new chapter in the current glaucoma management. It has the potential to address numerous challenges we face in our daily glaucoma practice, e.g., patient adherence, ocular toxicity, cost of glaucoma medications, etc. MIGS ab interno approach avoids conjunctival manipulation, preserving the more invasive surgery options. Future randomized control studies will hopefully provide us with knowledge about long-term efficacy, ideal patient selection, optimal location for device implantation, and cost-effectiveness data. ■
